Everolimus and long-term outcomes in renal transplantation

Transplantation

Volumn 92, Issue 3 SUPPL., 2011, Pages

  Campistol, Josep M ^a   De Fijter, Johan W ^b   Nashan, Björn ^c   Holdaas, Hallvard ^d   Vítko, Štefan ^e   Legendre, Christophe ^f  

^a UNIVERSITY OF BARCELONA   (Spain)

^b LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^c UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^d OSLO UNIVERSITY HOSPITAL   (Norway)

^e INSTITUTE FOR CLINICAL AND EXPERIMENTAL MEDICINE   (Czech Republic)

^f UNIVERSITÉ PARIS DESCARTES   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; AZATHIOPRINE; BASILIXIMAB; CALCINEURIN INHIBITOR; CLOBETASOL; CYCLOSPORIN A; DIURETIC AGENT; ERYTHROPOIETIN; EVEROLIMUS; GANCICLOVIR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LYMECYCLINE; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISOLONE; RAPAMYCIN; STEROID; SULFAMETHOXAZOLE; TACROLIMUS; TETRACYCLINE; TRIMETHOPRIM;

ACNE; ACUTE GRAFT REJECTION; ALLOTRANSPLANTATION; ANEMIA; ARTICLE; CARDIOVASCULAR DISEASE; DNA REPLICATION; DRUG ACTIVITY; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; EDEMA; GRAFT RECIPIENT; HEART DISEASE; HUMAN; HYPERLIPIDEMIA; KIDNEY FUNCTION; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; LONG TERM CARE; MEMBRANOPROLIFERATIVE GLOMERULONEPHRITIS; MOUTH ULCER; NEPHROTOXICITY; PRIORITY JOURNAL; PROTEINURIA; RISK FACTOR; TREATMENT OUTCOME;

GRAFT REJECTION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; SIROLIMUS; TREATMENT OUTCOME;

EID: 80051738799     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/TP.0b013e3182230900     Document Type: Article

References (138)

1. Hariharan S, Johnson CP, Bresnahan BA, et al. Improved graft survival after renal transplantation in the United States, 1988 to 1996. N Engl J Med 2000;342:605.
2. Meier-Kriesche H-U, Schold JD, Kaplan B. Long-term renal allograft survival: have we made significant progress or is it time to rethink our analytic and therapeutic strategies? Am J Transplant 2004;4:1289.
3. Meier-Kriesche H-U, Schold JD, Srinivas TR, et al. Lack of improvement in renal allograft survival despite a marked decrease in acute rejection rates over the most recent era. Am J Transplant 2004;4:378.
4. Campbell S, McDonald S, Chang S, et al. ANZDATA Registry. The 30th AnnualReport. Ch8Transplantation. Available at: http://www.anzdata.org.au/ anzdata/AnzdataReport/30thReport/Ch08Transplantation.pdf. Accessed January 3, 2011.
5. Chapman JR, O'Connell PJ, Nankivell BJ. Chronic renal allograft dysfunction. J Am Soc Nephrol 2005;16:3015.
6. Baluja P, Haragsim L, Laszik Z. Chronic allograft nephropathy. Adv Chronic Kidney Dis 2006;13:56.
7. Kreis HA, Ponticelli C. Causes of late renal allograft loss: chronic allograft dysfunction, death, and other factors. Transplantation 2001;71(suppl):SS5.
8. Nankivell BJ, Borrows RJ, Fung CL, et al. Calcineurin inhibitor nephrotoxicity: longitudinal assessment by protocol histology. Transplantation 2004;78:557.
9. Pascual M, Theruvath T, Kawai T, et al. Strategies to improve long-term outcomes after renal transplantation. N Engl J Med 2002;346:580.
10. Campistol JM, Boletis IN, Dantal J, et al. Chronic allograft nephropathy-a clinical syndrome: early detection and the potential role of proliferation signal inhibitors. Clin Transplant 2009;23:769.
11. Sagedal S, Nordal KP, Hartmann A, et al. The impact of cytomegalovirus infection and disease on rejection episodes in renal allograft recipients. Am J Transplant 2002;2:850.
12. Fishman JA, Rubin RH. Infection in organ-transplant recipients. N Engl J Med 1998;338:1741.
13. Kotton CN, Fishman JA. Viral infection in the renal transplant recipient. J Am Soc Nephrol 2005;16:1758.
14. Egli A, Binggeli S, Bodaghi S, et al. Cytomegalovirus and polyomavirus BK posttransplant. Nephrol Dial Transplant 2007;22(suppl 8):viii72.
15. Ojo AO. Cardiovascular complications after renal transplantation and their prevention. Transplantation 2006;82:603.
16. Kasiske BL, Snyder JJ, Gilbertson DT, et al. Cancer after kidney transplantation in the United States. Am J Transplant 2004;4:905.
17. Kuschal C, Thoms KM, Mori T, et al. Cyclosporin A, but not everolimus, inhibits DNA repair in human fibroblasts and lymphoblasts. Int J Clin Pharmacol Ther 2009;47:38.
18. O'Driscoll M, Jeggo PA. CsA can induce DNA double-strand breaks: implications for BMT regimens particularly for individuals with defective DNA repair. Bone Marrow Transplant 2008;41:983.
19. Campistol JM. Minimizing the risk of posttransplant malignancy. Transplantation 2009;87(suppl):S19.
20. Schena FP, Pascoe MD, Alberu J, et al. Conversion from calcineurin inhibitors to sirolimus maintenance therapy in renal allograft recipients: 24-month efficacy and safety results from the CONVERT trial. Transplantation 2009;87:233.
21. Bemelman FJ, de Maar EF, Press RR, et al. Minimization of maintenance immunosuppression early after renal transplantation: an interim analysis. Transplantation 2009;88:421.
22. Holdaas H, Bentdal Ø, Pfeffer P, et al. Early, abrupt conversion of de novo renal transplant patients from cyclosporine to everolimus: results of a pilot study. Clin Transplant 2008;22:366.
23. Nashan B, Curtis J, Ponticelli C, et al. Everolimus and reduced-exposure cyclosporine in de novo renal-transplant recipients: a three-year phase II, randomized, multicenter, open-label study. Transplantation 2004;78:1332.
24. Tedesco Silva H Jr, Cibrik D, Johnston T, et al. Everolimus plus reduced-exposure CsA versus mycophenolic acid plus standard-exposure CsA in renal-transplant recipients. Am J Transplant 2010;10:1401.
25. Vítko Š, Margreiter R, Weimar W, et al. Three-year efficacy and safety results from a study of everolimus versus mycophenolate mofetil in de novo renal transplant patients. Am J Transplant 2005;5:2521.
26. Tedesco Silva H Jr, Vitko S, Pascual J, et al. 12-month safety and efficacy of everolimus with reduced exposure cyclosporine in de novorenal transplant recipients. Transpl Int 2007;20:27.
27. Kauffman HM, Cherikh WS, Cheng Y, et al. Maintenance immunosuppression with target-of-rapamycin inhibitors is associated with a reduced incidence of de novo malignancies. Transplantation 2005;80:883.
28. Hussar DA. New drugs of 1999. J Am Pharm Assoc (Wash) 2000;40:181.
29. Schuler W, Sedrani R, Cottens S, et al. SDZ RAD, a new rapamycin derivative: pharmacological properties in vitro and in vivo. Transplantation 1997;64:36.
30. Taylor AL, Watson CJ, Bradley JA. Immunosuppressive agents in solid organ transplantation: mechanisms of action and therapeutic efficacy. Crit Rev Oncol Hematol 2005;56:23.
31. Bjornsti MA, Houghton PJ. The TOR pathway: a target for cancer therapy. Nat Rev Cancer 2004;4:335.
32. Nashan B. Review of the proliferation inhibitor everolimus. Expert Opin Investig Drugs 2002;11:1845.
33. Cole OJ, Shehata M, Rigg KM. Effect of SDZ RAD on transplant arteriosclerosis in the rat aortic model. Transplant Proc 1998;30:2200.
34. Salminen US, Alho H, Taskinen E, et al. Effects of rapamycin analogue SDZ RAD on obliterative lesions in a porcine heterotopic bronchial allograft model. Transplant Proc 1998;30:2204.
35. Augustine JJ, Bodziak KA, Hricik DE. Use of sirolimus in solid organ transplantation. Drugs 2007;67:369.
36. Kirchner GI, Meier-Wiedenbach I, Manns MP. Clinical pharmacokinetics of everolimus. Clin Pharmacokinet 2004;43:83.
37. Wyeth. Rapamune Summary of Product Characteristics. 2009. Available at: http://emc.medicines.org.uk/medicine/11734/XPIL/Rapamune+1mg+Oral+Solution/. Accessed July 30, 2010.
38. Novartis Pharmaceuticals. Certican summary of product characteristics. 2007.
39. Kovarik JM, Kalbag J, Figueiredo J, et al. Differential influence of two cyclosporine formulations on everolimus pharmacokinetics: a clinically relevant pharmacokinetic interaction. J Clin Pharmacol 2002;42:95.
40. Kovarik JM, Curtis JJ, Hricik DE, et al. Differential pharmacokinetic interaction of tacrolimus and cyclosporine on everolimus. Transplant Proc 2006;38:3456.
41. Lorber MI, Mulgaonkar S, Butt KMH, et al. Everolimus versus mycophenolate mofetil in the prevention of rejection in de novo renal transplant recipients: a 3-year randomized, multicenter, phase III study. Transplantation 2005;80:244.
42. Pascual J. Concentration-controlled everolimus (Certican): combination with reduced dose calcineurin inhibitors. Transplantation 2005;79(suppl):S76.
43. Budde K, Becker T, Arns W, et al. Analysis of renal function in everolimus/enteric-coated mycophenolate sodium treated de novo renal transplant recipients after calcineurin inhibitor withdrawal: the ZEUS study [abstract]. Am J Transplant 2009;9(suppl 2):259, 237.
44. Halloran PF. Molecular mechanisms of new immunosuppressants. Clin Transplant 1996;10:118.
45. Nankivell BJ, Borrows RJ, Fung CLS, et al. The natural history of chronic allograft nephropathy. N Engl J Med 2003;349:2326.
46. Nashan B. The role of Certican (everolimus, rad) in the many pathways of chronic rejection. Transplant Proc 2001;33:3215.
47. Lutz J, Zou H, Liu S, et al. Apoptosis and treatment of chronic allograft nephropathy with everolimus. Transplantation 2003;76:508.
48. Koch M, Mengel M, Poehnert D, et al. Effects of everolimus on cellular and humoral immune processes leading to chronic allograft nephropathy in a rat model with sensitized recipients. Transplantation 2007;83:498.
49. Vítko Š, Margreiter R, Weimar W, et al. Everolimus (Certican) 12-month safety and efficacy versus mycophenolate mofetil in de novo renal transplant recipients. Transplantation 2004;78:1532.
50. Aakhus S, Dahl K, Widerøe TE. Cardiovascular disease in stable renal transplant patients in Norway: morbidity and mortality during a 5-yr follow-up. Clin Transplant 2004;18:596.
51. Ducloux D, Kazory A, Chalopin J-M. Predicting coronary heart disease in renal transplant recipients: a prospective study. Kidney Int 2004;66:441.
52. Seckinger J, Sommerer C, Hinkel UP, et al. Switch of immunosuppression from cyclosporine A to everolimus: impact on pulse wave velocity in stable de-novo renal allograft recipients. J Hypertens 2008;26:2213.
53. Eisen H. Long-term cardiovascular risk in transplantation-insights from the use of everolimus in heart transplantation. Nephrol Dial Transplant 2006;21(suppl 3):iii9.
54. Eisen HJ, Tuzcu EM, Dorent R, et al. Everolimus for the prevention of allograft rejection and vasculopathy in cardiac-transplant recipients. N Engl J Med 2003;349:847.
55. Beijk MAM, Piek JJ. XIENCE V everolimus-eluting coronary stent system: a novel second generation drug-eluting stent. Expert Rev Med Devices 2007;4:11.
56. Grube E, Sonoda S, Ikeno F, et al. Six-and twelve-month results from first human experience using everolimus-eluting stents with bioabsorbable polymer. Circulation 2004;109:2168.
57. Tsuchiya Y, Lansky AJ, Costa RA, et al. Effect of everolimus-eluting stents in different vessel sizes (from the pooled FUTURE I and II trials). Am J Cardiol 2006;98:464.
58. Gordon PC, Applegate RJ, Hermiller JB, et al. Clinical and angiographic outcomes with an everolimus-eluting stent in large coronary arteries: the SPIRIT III 4.0 mm registry. Catheter Cardiovasc Interv 2010;75:179.
59. Stone GW, Midei M, Newman W, et al. Comparison of an everolimuseluting stent and a paclitaxel-eluting stent in patients with coronary artery disease. A randomized trial. JAMA 2008;299:1903.
60. Ruygrok PN, Desaga M, Van Den Branden F, et al. One year clinical follow-up of the XIENCE V Everolimus-eluting stent system in the treatment of patients with de novo native coronary artery lesions: the SPIRIT II study. EuroIntervention 2007;3:315.
61. Serruys PW, Ruygrok P, Neuzner J, et al. A randomised comparison of an everolimus-eluting coronary stent with a paclitaxel-eluting coronary stent: the SPIRIT II trial. EuroIntervention 2006;2:286.
62. Buell JF, Gross TG, Woodle ES. Malignancy after transplantation. Transplantation 2005;80(suppl):S254.
63. Weischer M, Röcken M, Berneburg M. Calcineurin inhibitors and rapamycin: cancer protection or promotion? Exp Dermatol 2007;16:385.
64. Dantal J, Soulillou J-P. Immunosuppressive drugs and the risk of cancer after organ transplantation [editorial]. N Engl J Med 2005;352:1371.
65. Marcén R, Pascual J, Tato AM, et al. Influence of immunosuppression on the prevalence of cancer after kidney transplantation. Transplant Proc 2003;35:1714.
66. Beuvink I, Boulay A, Fumagalli S, et al. The mTOR inhibitor RAD001 sensitizes tumor cells to DNA-damaged induced apoptosis through inhibition of p21 translation. Cell 2005;120:747.
67. Boulay A, Zumstein-Mecker S, Stephan C, et al. Antitumor efficacy of intermittent treatment schedules with the rapamycin derivative RAD001 correlates with prolonged inactivation of ribosomal protein S6 kinase 1 in peripheral blood mononuclear cells. Cancer Res 2004;64:252.
68. Fernández A, Marcén R, Pascual J, et al. Conversion from calcineurin inhibitors to everolimus in kidney transplant recipients with malignant neoplasia. Transplant Proc 2006;38:2453.
69. Majumder PK, Febbo PG, Bikoff R, et al. mTOR inhibition reverses Akt-dependent prostate intraepithelial neoplasia through regulation of apoptotic and HIF-1-dependent pathways. Nat Med 2004;10:594.
70. Motzer RJ, Escudier B, Oudard S, et al. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebocontrolled phase III trial. Lancet 2008;372:449.
71. Morelon E, Kreis H. Sirolimus therapy without calcineurin inhibitors: Necker Hospital 8-year experience. Transplant Proc 2003;35(suppl):52S.
72. Kasiske BL, Chakkera HA, Louis TA, et al. A meta-analysis of immunosuppression withdrawal trials in renal transplantation. JAmSoc Nephrol 2000;11:1910.
73. Oppenheimer F, Aljama P, Asensio Peinado C, et al. The impact of donor age on the results of renal transplantation. Nephrol Dial Transplant 2004;19(suppl 3):iii11.
74. Ruiz JC, Sánchez A, Rengel M, et al. Use of the new proliferation signal inhibitor everolimus in renal transplant patients in Spain: preliminary results of the EVERODATA registry. Transplant Proc 2007;39:2157.
75. Franco AF, Martini D, Abensur H, et al. Proteinuria in transplant patients associated with sirolimus. Transplant Proc 2007;39:449.
76. Ruiz JC, Campistol JM, Sanchez-Fructuoso A, et al. Early sirolimus use with cyclosporine elimination does not induce progressive proteinuria. Transplant Proc 2007;39:2151.
77. Diekmann F, Budde K, Oppenheimer F, et al. Predictors of success in conversion from calcineurin inhibitor to sirolimus in chronic allograft dysfunction. Am J Transplant 2004;4:1869.
78. Hiremath S, Fergusson D, Doucette S, et al. Renin angiotensin system blockade in kidney transplantation: a systematic review of the evidence. Am J Transplant 2007;7:2350.
79. Keane WF. Proteinuria: its clinical importance and role in progressive renal disease. Am J Kidney Dis 2000;35(suppl 1):S97.
80. Muirhead N, House A, Hollomby DJ, et al. Effect of valsartan on urinary protein excretion and renal function in patients with chronic renal allograft nephropathy. Transplant Proc 2003;35:2412.
81. Tedesco Silva H Jr, Kim YS, Lackova E, et al. Everolimus with reduced-dose cyclosporine: results from a randomized study in 833 de-novo renal-transplant recipients. Poster P371 presented at the 14th ESOT Congress, Paris, France, 30 August to 2 September 2009.
82. Pascual J, Marcén R, Ortuño J. Clinical experience with everolimus (Certican): optimizing dose and tolerability. Transplantation 2005;79(suppl):S80.
83. Kasiske B, Cosio FG, Beto J, et al. Clinical practice guidelines for managing dyslipidemias in kidney transplant patients: a report from the Managing Dyslipidemias in Chronic Kidney Disease Work Group of the National Kidney Foundation Kidney Disease Outcomes Quality Initiative. Am J Transplant 2004;4(suppl 7):13.
84. Mathis AS, Davé N, Knipp GT, et al. Drug-related dyslipidemia after renal transplantation. Am J Health Syst Pharm 2004;61:565.
85. Navaneethan SD, Perkovic V, Johnson DW, et al. HMG CoA reductase inhibitors (statins) for kidney transplant recipients. Cochrane Database Syst Rev 2009;CD005019.
86. Friemann S, Stopp K, Christ B, et al. Conversion to tacrolimus in hyperlipidemic patients. Transplant Proc 1999;31:41S.
87. Pascual J, Boletis IN, Campistol JM. Everolimus (Certican) in renal transplantation: a review of clinical trial data, current usage, and future directions. Transplant Rev 2006;20:1.
88. Barsoum RS, Morsey AA, Iskander IR, et al. The Cairo kidney center protocol for rapamycin-based sequential immunosuppression in kidney transplant recipients: 2-year outcomes. Exp Clin Transplant 2007;5:649.
89. Dean PG, Lund WJ, Larson TS, et al. Wound-healing complications after kidney transplantation: a prospective, randomized comparison of sirolimus and tacrolimus. Transplantation 2004;77:1555.
90. Durrbach A, Rostaing L, Tricot L, et al. Prospective comparison of the use of sirolimus and cyclosporine in recipients of a kidney from an expanded criteria donor. Transplantation 2008;85:486.
91. Troppmann C, Pierce JL, Gandhi MM, et al. Higher surgical wound complication rates with sirolimus immunosuppression after kidney transplantation: a matched-pair pilot study. Transplantation 2003;76:426.
92. Valente JF, Hricik D, Weigel K, et al. Comparison of sirolimus vs. mycophenolate mofetil on surgical complications and wound healing in adult kidney transplantation. Am J Transplant 2003;3:1128.
93. Albano L, Berthoux F, Moal M-C, et al. Incidence of delayed graft function and wound healing complications after deceased-donor kidney transplantation is not affected by de novo everolimus. Transplantation 2009;88:69.
94. Ponticelli C. Can mTOR inhibitors reduce the risk of late kidney allograft failure? Transpl Int 2008;21:2.
95. Hudes GR. Targeting mTOR in renal cell carcinoma. Cancer 2009;115(suppl):2313.
96. Guba M, von Breitenbuch P, Steinbauer M, et al. Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor. Nat Med 2002;8:128.
97. Contreras AG, Dormond O, Edelbauer M, et al. mTOR-understanding the clinical effects. Transplant Proc 2008;40(suppl):S9.
98. Cruzado JM. Nonimmunosuppressive effects of mammalian target of rapamycin inhibitors. Transplant Rev (Orlando) 2008;22:73.
99. Ormiston JA, Serruys PW, Regar E, et al. A bioabsorbable everolimuseluting coronary stent system for patients with single de-novo coronary artery lesions (ABSORB): a prospective open-label trial. Lancet 2008;371:899.
100. Vincenti F, Ramos E, Brattstrom C, et al. Multicenter trial exploring calcineurin inhibitors avoidance in renal transplantation. Transplantation 2001;71:1282.
101. Strehlau J, Pavlakis M, Lipman M, et al. The intragraft gene activation of markers reflecting T-cell-activation and-cytotoxicity analyzed by quantitative RT-PCR in renal transplantation. Clin Nephrol 1996;46:30.
102. Strehlau J, Nashan B, Schnakenburg C, et al. Organ specific T-cell growth factor and CTL gene activation in renal and liver transplant rejection. Transplantation 1999;67:S248.
103. Ekberg H, Grinyó J, Nashan B, et al. Cyclosporine sparing with mycophenolate mofetil, daclizumab and corticosteroids in renal allograft recipients: the CAESAR study. Am J Transplant 2007;7:560.
104. Schuurman HJ, Cottens S, Fuchs S, et al. SDZ RAD, a new rapamycin derivative: synergism with cyclosporine. Transplantation 1997;64:32.
105. Dubois S, Shou W, Haneline LS, et al. Distinct pathways involving the FK506-binding proteins 12 and 12.6 underlie IL-2-versus IL-15-mediated proliferation of T cells. Proc Natl Acad Sci USA 2003;100:14169.
106. Hirsch HH, Knowles W, Dickenmann M, et al. Prospective study of polyomavirus type BK replication and nephropathy in renal-transplant recipients. N Engl J Med 2002;347:488.
107. Ramos E, Drachenberg CB, Wali R, et al. The decade of polyomavirus BK-associated nephropathy: state of affairs. Transplantation 2009;87:621.
108. Schold JD, Rehman S, Kayler LK, et al. Treatment for BK virus: incidence, risk factors and outcomes for kidney transplant recipients in the United States. Transpl Int 2009;22:626.
109. Ciancio G, Burke GW, Gaynor JJ, et al. A randomized long-term trial of tacrolimus/sirolimus versus tacrolimums/mycophenolate versus cyclosporine/sirolimus in renal transplantation: three-year analysis. Transplantation 2006;81:845.
110. Gallon L, Perico N, Dimitrov BD, et al. Long-term renal allograft function on a tacrolimus-based, pred-free maintenance immunosuppression comparing sirolimus vs. MMF. Am J Transplant 2006;6:1617.
111. Mendez R, Gonwa T, Yang HC, et al. A prospective, randomized trial of tacrolimus in combination with sirolimus or mycophenolate mofetil in kidney transplantation: results at 1 year. Transplantation 2005;80:303.
112. Vitko S, Wlodarczyk Z, Kyllönen L, et al. Tacrolimus combined with two different dosages of sirolimus in kidney transplantation: results of a multicenter study. Am J Transplant 2006;6:531.
113. Meier-Kriesche HU, Schold JD, Srinivas TR, et al. Sirolimus in combination with tacrolimus is associated with worse renal allograft survival compared to mycophenolate mofetil combined with tacrolimus. Am J Transplant 2005;5:2273.
114. Chan L, Greenstein S, Hardy MA, et al. Multicenter, randomized study of the use of everolimus with tacrolimus after renal transplantation demonstrates its effectiveness. Transplantation 2008;85:821.
115. Vitko S, Hene R, Langer R, et al. Everolimus with low or very low exposure of tacrolimus in de novo renal transplant recipients: the ASSET study. Oral presentation at the 14th ESOT Congress, Paris, France, 30 August to 2 September 2009.
116. Humar A, Ramcharan T, Denny R, et al. Are wound complications after a kidney transplant more common with modern immunosuppression? Transplantation 2001;72:1920.
117. Mehrabi A, Fonouni H, Wente M, et al. Wound complications following kidney and liver transplantation. Clin Transplant 2006;20(suppl 17):97.
118. Sansalone CV, Aseni P, Minetti E, et al. Is lymphocele in renal transplantation an avoidable complication? Am J Surg 2000;179:182.
119. Morath C, Zeier M. Review of the antiproliferative properties of mycophenolate mofetil in non-immune cells. Int J Clin Pharmacol Ther 2003;41:465.
120. Allison AC, Eugui EM. Mycophenolate mofetil and its mechanisms of action. Immunopharmacology 2000;47:85.
121. Gamboa-Bobadilla GM, Killingsworth C. Large-volume reduction mammaplasty: the effect of body mass index on postoperative complications. Ann Plast Surg 2007;58:246.
122. Margreiter R, Vitko Š, Whelchel J, et al. Post-operative tissue regeneration in renal transplantation: comparable outcome with everolimus or MMF [abstract]. Transplantation 2008;86(suppl 2):188, 538.
123. Legendre C, Cassuto E, Rostaing L, et al. The incidence of delayed graft function (DGF) following kidney transplantation is not affected by de novo everolimus therapy [abstract]. Transplantation 2008;86(suppl 2):159, 451.
124. Åsberg A, Midtvedt K, Line PD, et al. Calcineurin inhibitor avoidance with daclizumab, mycophenolate mofetil, and prednisolone in DR-matched de novo kidney transplant recipients. Transplantation 2006;82:62.
125. Ekberg H, Tedesco-Silva H, Demirbas A, et al. Reduced exposure to calcineurin inhibitors in renal transplantation. N Engl J Med 2007;357:2562.
126. Flechner SM, Kobashigawa J, Klintmalm G. Calcineurin inhibitorsparing regimens in solid organ transplantation: focus on improving renal function and nephrotoxicity. Clin Transplant 2008;22:1.
127. Baczkowska T, Durlik M. Calcineurin inhibitor sparing immunosuppressive regimens in kidney allograft recipients. Pol Arch Med Wewn 2009;119:318.
128. Russ G. Stratifying risk and targeting immunosuppressive strategies. Transplant Proc 2008;40:S60.
129. Gude E, Gullestad L, Arora S, et al. Benefit of early conversion from CNI-based to everolimus-based immunosuppression in heart transplantation. J Heart Lung Transplant 2010;29:641.
130. Budde K, Becker T, Arns W, et al. Everolimus-based, calcineurin- inhibitor-free regimen in recipients of de-novo kidney transplants: an open-label, randomised, controlled trial. Lancet 2011;377:837.
131. Pietruck F, Becker T, Arns W, et al. Efficacy and safety of an everolimus/enteric-coated mycophenolate sodium regimen after calcineurin inhibitor withdrawal in de novo renal transplant patients: results of the ZEUS trial [abstract]. Am J Transplant 2009;9(suppl 2):499, 1093.
132. Letavernier E, Legendre C. mToR inhibitors-induced proteinuria: mechanisms, significance, and management. Transplant Rev (Orlando) 2008;22:125.
133. Vitko S, Hene R, Langer R, et al. Everolimus with low or very low exposure of tacrolimus in de novo renal transplant recipients: the ASSET study [abstract]. Transpl Int 2009;22(suppl 2):53, O-201.
134. Kuypers DR. Immunotherapy in elderly transplant recipients: a guide to clinically significant drug interactions. Drugs Aging 2009;26:715.
135. Li C, Yang CW. The pathogenesis and treatment of chronic allograft nephropathy. Nat Rev Nephrol 2009;5:513.
136. Rigatto C, Parfrey P. Therapy insight: management of cardiovascular disease in the renal transplant recipient. Nat Clin Pract Nephrol 2006;2:514.
137. Bahous SA, Stephan A, Barakat W, et al. Aortic pulse wave velocity in renal transplant patients. Kidney Int 2004;66:1486.
138. Paoletti E, Amidone M, Cassottana P, et al. Effect of sirolimus on left ventricular hypertrophy in kidney transplant recipients: a 1-year non-randomized controlled trial. Am J Kidney Dis 2008;52:324.